MD-230254
MD-230254 is a reversible, competitive and selective inhibitor inhibitor of MAO-B with an IC50 value of 1.8 nM. MD-230254 can be used for the study of MAO-B-related neurodegenerative diseases including Parkinson’s disease and Alzheimer’s disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 147807-20-3
- Formule: C18H15N3O3
- Masse moléculaire:321.33
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
MAO-B |
In Vitro
MD-230254 potently and selectively inhibits MAO-B in rat liver mitochondria fraction with an IC50 of 1.8 nM and a MAO-A/MAO-B selectivity ratio of >56,000[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 147807-20-3
-
Masse moléculaire 321.33
-
Formule C18H15N3O3
-
SMILES
N#CCCN1N=C(C2=CC=C(OCC3=CC=CC=C3)C=C2)OC1=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Pureté et documentation
Références
[1]. Lebreton L, et al. Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. J Med Chem. 1995;38(24):4786-4792. [Content Brief]
[2]. Yoshimoto M, et al. Synthesis and characterization of novel radiofluorinated probes for positron emission tomography imaging of monoamine oxidase B. J Labelled Comp Radiopharm. 2019;62(9):580-587. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)